(Q42981362)

English

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

scientific article published on 8 August 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

Patrick Marcellin

1

object named as

Patrick Marcellin

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

6

object named as

Andrzej Horban

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

16

object named as

Mario Rizzetto

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Hugo Cheinquer

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Manuela Curescu

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Geoffrey M Dusheiko

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peter Ferenci

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Donald Jensen

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Gabriella Lengyel

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Alessandra Mangia

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Denis Ouzan

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Massimo Puoti

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Maribel Rodriguez-Torres

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mitchell L Shiffman

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Manuela Schmitz

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Fernando Tatsch

15

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

8 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2039-2050

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Outcomes of treatment for hepatitis C virus infection by primary care providers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.25892

21 January 2018

Identifiers

10.1002/HEP.25892

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42981362&oldid=1975635706"